Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.
- DOI
- 10.1016/j.ygyno.2023.01.010
- Published
- 2023 Apr
- Container
- Gynecologic oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ygyno.2023.01.010,
title = {Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.},
author = {Tewari KS and Sill MW and Birrer MJ and Penson RT and Huang H and Moore DH and Ramondetta LM and Landrum LM and Oaknin A and Reid TJ and Leitao MM and Michael HE and Monk BJ},
year = {2023},
journal = {Gynecologic oncology},
doi = {10.1016/j.ygyno.2023.01.010},
url = {https://doi.org/10.1016/j.ygyno.2023.01.010}
}RIS
TY - JOUR TI - Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study. AU - Tewari KS AU - Sill MW AU - Birrer MJ AU - Penson RT AU - Huang H AU - Moore DH AU - Ramondetta LM AU - Landrum LM AU - Oaknin A AU - Reid TJ AU - Leitao MM AU - Michael HE AU - Monk BJ PY - 2023 JO - Gynecologic oncology DO - 10.1016/j.ygyno.2023.01.010 UR - https://doi.org/10.1016/j.ygyno.2023.01.010 ER -
APA
KS, T., MW, S., MJ, B., RT, P., H, H., DH, M., LM, R., LM, L., A, O., TJ, R., MM, L., HE, M., & BJ, M. (2023). Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.. Gynecologic oncology. https://doi.org/10.1016/j.ygyno.2023.01.010
Source records
- pubmed · retrieved 2026-11-11T00:08:52.987Z